SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1182 participants.

Also called NCT07944066

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,182 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07944066
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07944066. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-10 (actual); primary completion 2031-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis
Acronym
SAVE-AS
Condition
Aortic Valve Stenosis
Intervention (Drug)
Enavogliflozin
Intervention (Drug)
Placebo
Lead sponsor
Samsung Medical Center (class: other)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct07944066
Content hash
587ffe2bae07a9413c21948221ac54a70d673aca76be702bebfc96cfbcc9dace